| Date | Title | Description |
| 08.03.2025 |
Cramer’s Lightning Round: Rigetti Computing is ‘a meme stock’ | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Fiserv: “I think they’re one of the greates... |
| 09.08.2024 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE on Behalf of Shareholders | NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relat... |
| 17.07.2024 | US-based AI startups that raised over $100 million in funding in 2024 | ETtech
Venture capital investors cannot get enough of the growing artificial intelligence (AI) wave, with startups in the US roping in big funding in the first half of 2024. Even as Indian AI startups saw a dip in funding, those in the US d... |
| 11.06.2024 | QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors | Industry veteran Williamson brings nearly three decades' experience as a leader in neuroscience R&D at organizations including Eli Lilly and Company, Lundbeck, Parexel, and Acadia Pharmaceuticals
Former Karuna CFO Brown brings more than... |
| 12.03.2024 | Nvidia стала делать ставку на все технологии, связанные с ИИ. За год компания инвестировала в 30 стартапов $1,55 млрд... | Последний год для производителя чипов Nvidia стал поворотным, поскольку он превзошел все ожидания и к концу февраля достиг рыночной капитализации более $2 трлн. Это сделало компанию крупнейшей по рыночной капитализации после Microsoft и App... |
| 11.03.2024 | It's not just chips. Nvidia is betting on other tech that could be impacted by AI. | Tech It's not just chips. Nvidia is betting on other tech that could be impacted by AI.
Lloyd Lee
2024-03-11T03:42:26Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email icon An envelope. It indicate... |
| 04.03.2024 | NVIDIA Surpasses Saudi Aramco to Become World's 3rd Richest Company | Inno Flores, Tech Times 04 March 2024, 11:03 pm
NVIDIA, the AI chipmaker, continues its meteoric rise in the market, surpassing Saudi Aramco to become the third most valuable company globally and in the United States. (Photo : Justin Sulliv... |
| 29.04.2021 | Recursion Pharmaceuticals Jumps in Debut After $436 Million IPO | First investment made by our partners during their tenure at Mubadala Ventures; Recursion Pharmaceuticals Inc., uses machine learning to hunt for new therapies, rose 74% in its trading debut after exceeding goals for its initial public offe... |
| 06.10.2020 | Catalio Capital Management closes $100M venture fund | Catalio Capital Management, a Baltimore-based investment firm focused on biomedical technology companies, said Tuesday that it closed its second venture fund with $100 million.
The fund, called Catalio Nexus II, was oversubscribed. Backed b... |
| 10.09.2020 | Recursion Raises $239M in Series D Equity Financing | Recursion, a Salt Lake City, UT-based digital biology company industrializing drug discovery, raised $239m in Series D financing.
The round was led by Leaps by Bayer, the impact investment arm of Bayer AG, with participation from new invest... |
| 10.09.2020 | Recursion raises $239M in Series D funding to revolutionize and accelerate drug discovery using artificial intelligence | Recursion, a Salt Lake City-based biotech startup using artificial intelligence technology for drug discovery, today announced that it has raised $239 million in equity financing to advance technology-enabled drug discovery platform and pip... |
| 10.09.2020 | Recursion raises $239M in Series D, partners with lead investor Bayer | “We have made significant progress since our last financing a year ago, doubling the number of clinical and preclinical programs in our pipeline, doubling the size of our proprietary database of cellular images and significantly expanding t... |
| 09.09.2020 | Recursion Pharma nets $239M, plus an AI research contract with Bayer | Recursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic diseases of the lung, heart, kidney and more.
The German drugmaker to... |
| 09.09.2020 | Recursion Pharma nets $239M, plus an AI research contract with Bayer | Recursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic diseases of the lung, heart, kidney and more.
Sponsored by Agilent Te... |
| 08.05.2020 | Ex-AstraZeneca exec Kristen Buck hops aboard Icon as CMO; Immunocore taps Brian DiDonato as CFO | Kristen Buck
→ Prominent CRO player Icon is bolstering its leadership, with Kristen Buck taking the reins as CMO.
For slightly more than a year and a half, Buck was the SVP & chief of clinical development at Optum, part ... |
| 11.11.2019 | Investors just poured more than $1 billion into startups using AI to tackle every part of healthcare. Here are the 5 healthcare AI startups raking in the most cash. | Dr. Ali Parsa, the CEO of Babylon Health. Jack Lewis Williams for Tailor Made London This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
The deal count for VC-backed healthcare deals is on pa... |
| 27.09.2019 | How To Spot A Synthetic Biology Unicorn | Biotech is projected to reach $775 billion by 2024, but dozens of companies in the field of ... [+] synthetic biology are creating magical tools to go beyond that. Look here for the next unicorn. Jelena Trmčić for SynBioBeta |
| 23.08.2019 | Ignyta founder boosts team at his new cancer startup; Cytomx CMO hits the exit | Jonathan Lim Erasca
→ Ignyta founder and ex-CEO Jonathan Lim is beefing up the team at Erasca, his new startup dedicated to erasing cancer. Genentech vet Gary Yeung has been promoted to chief operating and financial offi... |
| 16.07.2019 | AI drug discovery company Recursion Pharmaceuticals raises $121M Series C | Recursion’s technology works by generating millions of cellular images and using AI-based software as a way to analyze the data set and screen potential therapeutic compounds against a variety of diseased cells.
The new capital will go towa... |
| 16.07.2019 | Recursion Pharmaceuticals Raises $121M in Series C Financing | Recursion Pharmaceuticals, a Salt Lake City, UT-based next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, closed a $121m Series C financing.
The round was... |
| 15.07.2019 | AI drug prospector Recursion Pharma nets $121M for its clinical programs | Machine learning-powered drug discoverer Recursion Pharmaceuticals has secured $121 million in new financing for its artificial intelligence programs.
The proceeds will help the former Fierce 15 winner build out its automated drug discovery... |
| 15.07.2019 | AI drug prospector Recursion Pharma nets $121M for its clinical programs | Machine learning-powered drug discoverer Recursion Pharmaceuticals has secured $121 million in new financing for its artificial intelligence programs.
Sponsored by Agilent Technologies
How would you like to win free bench space at Lab Centr... |
| 05.06.2018 | Recursion Pharmaceuticals Raises $20.5M Credit Facility from Square 1 Bank | Recursion Pharmaceuticals, a Salt Lake City-based innovative biotechnology company specializing in artificial intelligence enabled drug discovery, raised a $20.5m credit facility.
Square 1 Bank, a division of Pacific Western Bank, provided ... |
| 15.05.2018 | With new $600M fund, CRV expands into bioengineering investment, adds strategic growth stage deals | In addition to bioengineering, Fund XVII will also invest in enterprise, consumer-centered companies, according to the blog entry.
Axios reported that the fund’s strategy actually marks a change from CRV’s initial plans to have a separate f... |
| 26.03.2018 | This is how AI will shape drug discovery | An oft-quoted statistic is that it takes 12 years and almost $2 billion dollars to bring an average drug to market. That is the raison d’être for the biotech VC industry, which saw $10 billion of capital invested in startups in 2017 alone, ... |
| 05.10.2017 | Recursion Pharmaceuticals Raises $60M in Series B Financing | Recursion Pharmaceuticals, a Salt Lake City, CA-based biotechnology company, raised $60m in Series B financing.
The round, which brings total capital raised to more than $80m, was led by Data Collective (DCVC), with participation from Lux C... |
| 03.10.2017 | Term Sheet — Tuesday, October 3 | DIRTY DEALINGS
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
But as I noted before, the numbers didn’t add up. Yesterday, Bloomberg published a story about how the company has overstated it... |
| 03.10.2017 | Drug discovery startup Recursion raises $60 million in Series B from Data Collective | Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC).
Recursion started out in 2014 on a mission to identify 100 new treatments in 10 years. That’s a lofty... |
| 19.07.2017 | The role of AI in the future of health care | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
American physician and surgeon William J. Mayo, o... |
| 08.02.2017 | Recursion Pharmaceuticals Receives $4M Credit Facility from Square 1 Bank | Recursion Pharmaceuticals, Inc., a Salt Lake City-based pharmaceutical discovery company, received a $4m credit facility.
Square 1 Bank, a division of Pacific Western Bank, provided the financing.
The company intends to use the proceeds to ... |
| 22.11.2016 | Term Sheet — Tuesday, November 22 | ET CETERA
A few quick notes on today’s deal bonanza, which we can expect to continue through the end of the year.
Paid Content How can you protect what you can't see? From ExtraHop
Meanwhile Fortune’s John Kell has the scoop on another beve... |
| 22.11.2016 | Recursion Pharmaceuticals Closes Additional $2.15M in Series A Funding | Recursion Pharmaceuticals, a Salt Lake City, UT-based drug discovery company, closed an additional $2.15M in Series A funding.
The additional funding, which brought the total amount raised in the round to $15.05M, came from several individu... |
| 25.10.2016 | Recursion Pharmaceuticals Announces John Pereira, MBA as Chief Operating Officer | SALT LAKE CITY–(BUSINESS WIRE)–October 25, 2016–
Recursion Pharmaceuticals, an emerging biotech in Salt Lake City, today announced that successful and serial technology entrepreneur and executive John Pereira, MBA, has joined the team as Ch... |
| 03.10.2016 | Recursion Pharma Raises $13M in Funding | Recursion Pharmaceuticals, a Salt Lake City, UT-based drug discovery company, raised $12.9m in Series A round of funding.
The round was led by Lux Capital, with participation from Obvious Ventures, Epic Ventures, Data Collective, AME Cloud ... |
| - | The Path to Precision Medicine | We believe data-driven companies can create the most powerful solutions to our world’s biggest problems. We have been increasingly excited about the intersection of data science and healthcare / biology and have already made several investm... |
| - | AstraZeneca's coronavirus vaccine hit a snag | Welcome to Business Insider's daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday.
Hollis Johnson/Business Insider
Hello,
Hope you all had g... |
| - | With new $600M fund, CRV expands into bioengineering investment, adds strategic growth stage deals | Early stage venture capital firm CRV has closed a $600 million fund that accomplishes a couple of firsts for the venture firm. The fund will embrace strategic growth stage investments as well as early-stage deals and adds bioengineering to ... |
| - | This is how AI will shape drug discovery | As healthcare venture capitalists, we specialize in technologies that have the potential to transform large markets in healthcare. Earlier this year, we predicted that 2018 would be a year of venture and M&A activity across the pharma v... |
| - | Biotech startup with AlphaGo-type AI approach snags $30M | In the world of artificial intelligence and machine learning, Google Deepmind’s AlphaGo program defeating world champion Lee Sedol at the game Go on March 19, 2016, was a watershed moment. It showed, among other things, that if an AI algori... |
| - | Recursion raises $239M in Series D, partners with lead investor Bayer | A startup developing artificial intelligence technology for drug discovery is partnering with a large German drugmaker in connection with its most recent investment round.
Salt Lake City-based Recursion Pharmaceuticals said Wednesday that i... |
| - | Going Remote Pt. III: Supporting the Mental Health of Your Team | As the weeks go by and we continue to shelter in place (or begin to open, depending on where you are), each of us is encountering different challenges when it comes to working remotely. We’ve had a number of interviews with leaders across o... |
| - | The AI-Powered Consumer Startup Revolution is Coming | As artificial intelligence and data science have begun to transform enterprise software, one area where we are excited to see more innovation is in AI-first consumer software startups. Over the past five years, we have seen a proliferation ... |
| - | AI drug discovery company Recursion Pharmaceuticals raises $121M Series C | Salt Lake City-based biotech Recursion Pharmaceuticals, which is part of the group of companies looking to use AI technology to accelerate drug development, has raised a $121 million Series C financing round led by Scottish Mortgage Investm... |
